Home » CROATIA'S PLIVA SELLS PROPRIETARY DRUG IN U.S.
CROATIA'S PLIVA SELLS PROPRIETARY DRUG IN U.S.
Croatian pharmaceutical concern Pliva (PLV.xq.L: Quote, Profile, Research) said on Wednesday it had sold a drug from its failed proprietary business in the U.S. for an immediate payment of $32 million and potentially more in the future. Pliva said it had made an agreement to sell VoSpire ER, a drug for the relief of bronchospasm, to a privately held specialty pharmaceutical company, Dava Pharmaceuticals Inc.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct